Anh D Le

US Patent:

8572746, Oct 29, 2013

Filed:

Jan 21, 2010

Appl. No.:

12/691631

Inventors:

Athina Markopoulou - Irvine CA, US
Fabio Soldo - Irvine CA, US
Anh Le - Irvine CA, US

Assignee:

The Regents of The University of California - Oakland CA

International Classification:

H04L 29/06

US Classification:

726 25

Abstract:

A method is provided for determining a rating of a likelihood of a victim system receiving malicious traffic from an attacker system at a point in time. The method comprises: generating a first forecast from a time series model based on past history of attacks by the attacker system; generating a second forecast from a victim neighborhood model based on similarity between the victim system and peer victim systems; generating a third forecast from a joint attacker-victim neighborhood model based on correlation between a group of attacker systems including the attacker system and a group of victim systems including the victim system; and determining the rating of the likelihood of the victim system receiving malicious traffic from the attacker system at the point in time based on the first forecast, the second forecast, and the third forecast.

US Patent:

20080038381, Feb 14, 2008

Filed:

Jun 22, 2007

Appl. No.:

11/767328

Inventors:

Anh Le - Los Angeles CA, US
Qunzhou Zhang - South Pasadena CA, US

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

A61K 36/82
A61K 31/352
A61P 17/02

US Classification:

424729000, 514456000

Abstract:

A composition comprising a green tea extract (GTE) or its major component, (−)-epigallocatechin-3-gallate (EGCG). Also disclosed is a method of using the composition for keloid scar therapy.

US Patent:

20120128636, May 24, 2012

Filed:

Jan 20, 2010

Appl. No.:

13/145541

Inventors:

Anh D. Le - La Mirada CA, US
Qunzhou Zhang - South Pasadena CA, US
Songtao Shi - Irvine CA, US

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

A61K 35/12
A61P 1/00
A61P 3/10
A61P 19/02
C12N 5/0775
A61P 29/00

US Classification:

424 937, 435325

Abstract:

The present invention relates to gingiva derived messenchymal stem cells (GMSCs). More specifically, the invention provides compositions and methods of using GMSCs to regulate inflammatory response in the setting of normal versus pathological wound healing and to treat inflammatory and/or autoimmune diseases.

US Patent:

20130295058, Nov 7, 2013

Filed:

Jul 14, 2011

Appl. No.:

13/809876

Inventors:

Anh D. Le - La Mirada CA, US
Qunzhou Zhang - San Gabriel CA, US

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

A61K 35/28

US Classification:

424 937, 435375

Abstract:

Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitity.

US Patent:

20200295326, Sep 17, 2020

Filed:

Jun 1, 2020

Appl. No.:

16/889168

Inventors:

- La Jolla CA, US
Weiyi Lu - La Jolla CA, US
Yang Shi - La Jolla CA, US
Anh V. Le - La Jolla CA, US

International Classification:

H01M 2/10
H01M 2/34
H01M 10/0525
H01M 10/058
H01M 4/62
B60L 50/64
H01M 10/04
H01M 10/42

Abstract:

A method of manufacturing a battery includes introducing a first material to the battery, providing an anode, a cathode and a separator of the battery; and assembling the anode, the separator and the cathode. The first material is configured and arranged to increase the internal impedance of the battery upon mechanical or thermal loading.

US Patent:

20180215666, Aug 2, 2018

Filed:

Jul 28, 2016

Appl. No.:

15/747617

Inventors:

- Oakland CA, US
Tze Han Chen - La Jolla CA, US
Anh V. Le - San Diego CA, US

International Classification:

C04B 26/28
C04B 26/14
B29C 70/60
C04B 26/18
C04B 26/06

Abstract:

The disclosure features methods of forming composite materials, and the composite materials formed by such methods. The methods include forming a mixture that includes a binder material and a filler material, and applying a pressure of at least 10 MPa to the mixture to form the composite material, where the composite material thus formed includes less than 9% by weight of the binder material, less than 18% by volume of the binder material, or both, and has a flexural strength of at least 3 MPa.

US Patent:

20160129043, May 12, 2016

Filed:

Jun 24, 2014

Appl. No.:

14/896891

Inventors:

- Los Angeles CA, US
Xingtian XU - South Pasadena CA, US
Chider CHEN - San Gabriel CA, US
Anh D. Le - La Mirada CA, US

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

A61K 35/28
C12N 5/0775

Abstract:

This invention relates in general to a mesenchymal stem cell (MSC) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells. More particularly, this invention relates to the isolation and applications of the neural crest derived gingiva mesenchymal stem cells and/or mesoderm derived gingiva mesenchymal stem cells. This invention also relates to a composition comprising a neural crest derived gingiva mesenchymal stem cell and/or a mesoderm derived gingiva mesenchymal stem cell. This composition may be used for wound healing and/or in the treatment of inflammatory and/or autoimmune diseases.